Suppr超能文献

蛋白激酶RNA样内质网激酶及磷酸化真核起始因子2α在胰腺导管腺癌中的表达及临床意义

Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2α in Pancreatic Ductal Adenocarcinoma.

作者信息

Wang Eric M, Akasaka Hironari, Zhao Jun, Varadhachary Gauri R, Lee Jeffrey E, Maitra Anirban, Fleming Jason B, Hung Mien-Chie, Wang Huamin, Katz Matthew H G

机构信息

Anatomic Pathology.

Gastrointestinal Medical Oncology.

出版信息

Pancreas. 2019 Mar;48(3):323-328. doi: 10.1097/MPA.0000000000001248.

Abstract

OBJECTIVES

Endoplasmic reticulum stress and subsequent phosphorylation of eukaryotic initiation factor 2α (eIF2α) by protein kinase R-like endoplasmic reticulum kinase (PERK) plays an important role in the development and chemoresistance of pancreatic ductal adenocarcinoma (PDAC). However, the expression and significance of phosphorylated eIF2α (p-eIF2α) and PERK in PDAC have not been examined.

METHODS

We examined p-eIF2α and PERK expression in 84 PDAC and paired normal pancreas samples by immunohistochemistry and Western blotting and correlated the results with clinicopathologic parameters and survival.

RESULTS

Mean PERK H score was 140.8 in PDAC compared with 82.1 in normal pancreas (P < 0.001). High p-eIF2α expression was present in 56% of PDACs versus 7.6% of normal pancreases (P < 0.001). High PERK and p-eIF2α expression correlated with shorter overall survival (P = 0.048 and P = 0.03, respectively). By multivariate analysis, high p-eIF2α (P = 0.01), positive margin (P = 0.002), and lymph node metastasis (P = 0.01) were independent prognosticators for survival.

CONCLUSIONS

The expression levels of PERK and p-eIF2α are higher in PDAC than those in normal pancreas. High levels of PERK and p-eIF2α are predictors of shorter survival in PDAC patients, suggesting that PERK and eIF2α could be promising targets in PDAC.

摘要

目的

内质网应激以及随后蛋白激酶R样内质网激酶(PERK)对真核起始因子2α(eIF2α)的磷酸化在胰腺导管腺癌(PDAC)的发生发展及化疗耐药中起重要作用。然而,磷酸化eIF2α(p-eIF2α)和PERK在PDAC中的表达及意义尚未得到研究。

方法

我们通过免疫组织化学和蛋白质印迹法检测了84例PDAC及其配对的正常胰腺组织样本中p-eIF2α和PERK的表达,并将结果与临床病理参数及生存情况进行关联分析。

结果

PDAC中PERK的平均H评分为140.8,而正常胰腺中为82.1(P<0.001)。56%的PDAC中存在高p-eIF2α表达,而正常胰腺中这一比例为7.6%(P<0.001)。高PERK和p-eIF2α表达与较短的总生存期相关(分别为P=0.048和P=0.03)。多因素分析显示,高p-eIF2α(P=0.01)、切缘阳性(P=0.002)和淋巴结转移(P=0.01)是生存的独立预后因素。

结论

PDAC中PERK和p-eIF2α的表达水平高于正常胰腺。高水平的PERK和p-eIF2α是PDAC患者生存期较短的预测指标,提示PERK和eIF2α可能是PDAC中有前景的治疗靶点。

相似文献

引用本文的文献

本文引用的文献

5
Pancreatic cancer.胰腺癌。
Lancet. 2016 Jul 2;388(10039):73-85. doi: 10.1016/S0140-6736(16)00141-0. Epub 2016 Jan 30.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验